Acute kidney injury in patients treated with immune checkpoint inhibitors.
Shruti GuptaSamuel A P ShortMeghan E SiseJason M ProsekSethu M MadhavanMaria Jose SolerMarlies OstermannSandra M HerrmannAla AbudayyehShuchi AnandIlya GlezermanShveta S MotwaniNaoka MurakamiRimda WanchooDavid I Ortiz-MeloArash RashidiBen SprangersVikram AggarwalA Bilal MalikSebastian LoewChristopher A CarlosWei-Ting ChangPazit BeckermanZain MithaniChintan V ShahAmanda D RenaghanSophie De SeigneuxLuca CampedelAbhijat KitchluDaniel Sanghoon ShinSunil RangarajanPriya DeshpandeGaia CoppockMark EijgelsheimHarish SeethapathyMeghan D LeeIan A StrohbehnDwight H OwenMarium HusainClara Garcia-CarroSheila BermejoNuttha LumlertgulNina SeylanovaLucy FlandersBusra IsikOmar MamloukJamie S LinPablo GarciaAydin KaghazchiYuriy KhaninSheru K KansalEls WautersSunandana ChandraKai M Schmidt-OttRaymond K HsuMaria C TioSuraj Sarvode MothiHarkarandeep SinghDeborah SchragKenar D JhaveriKerry L ReynoldsFrank B CortazarDavid E Leafnull nullPublished in: Journal for immunotherapy of cancer (2022)
Patients who developed ICPi-AKI were more likely to have impaired renal function at baseline, use a PPI, and have extrarenal irAEs. Two-thirds of patients had renal recovery following ICPi-AKI. Treatment with corticosteroids was associated with improved renal recovery.